Scanogen square logo ABOUT US TECHNOLOGY


Scanogen Entrance


February 10, 2017
Scanogen receives a new grant for $3 million from the NIH to develop a rapid assay for Tuberculosis detection.
July 5, 2016
Scanogen is granted two U.S. patents for inventions that use DNA supercoiling to detect biomolecules. US 9,382,578 describes circular biosensors that compact when target molecules are present in the sample.  US 9,382,580 describes Twist-Biosensor, a single molecule approach in which DNA tethered beads are displaced when target molecules are present in the sample.
June 20, 2016
A  patent is filed with the U.S. Patent Office to protect the imaging system used by the Scanogen instrument.
February 1, 2016
Scanogen moves to new facilities. The new space has renovated laboratories and offices, with a total area of 4,000 sq ft.  
October 1, 2015
Scanogen TB assay is described in the  TB Diagnostics Technology and Market Landscape report. “In the context of limited-resource setting TB diagnosis, Single Molecule Scanning may offer important advantages over the available amplification-based molecular platforms.”
May 15, 2014
Scanogen receives two new SBIR grants, from the National Human Genome Research Institute, and the National Institute of Allergy and Infectious Diseases.
February 6, 2014
An international PCT patent is filed to protect the Single Molecule Scanning technique. 
September 24, 2013
A U.S. Patent is filed to protect an alternative method to use the Twist-Biosensor.
September 19, 2013
Scanogen receives grant from the IMAT program of the National Cancer Institute.
January 16, 2013
Scanogen receives phase I SBIR grant from the National Human Genome Research Institute.
October 10, 2012
An international PCT patent is filed to protect the invention of the Twist-Biosensor.
October 31, 2011
Scanogen is funded and registered to operate in Maryland.

home link
2016 Scanogen Inc.

3102 Lord Baltimore Dr., Suite 214, Baltimore, MD, 21244 |